Sign in

    Tom Schrader • BTIG

    Tom Schrader's questions to NRX Pharmaceuticals Inc (NRXP) leadership

    Tom Schrader's questions to NRX Pharmaceuticals Inc (NRXP) leadership • Q2 2025

    Question

    Tom Schrader of BTIG questioned the rationale for seeking an accelerated approval pathway for NRX-101, given its conventional clinical endpoints, and asked whether the new Commissioner's National Priority Voucher (CNPV) could be sold like previous voucher types.

    Answer

    Jonathan Javitt, Founder, Chairman and CEO, clarified that the CNPV is not sellable and NRXP's sole objective is rapid drug delivery to patients. He explained that NRX-101's trial demonstrated reductions in akathisia and suicidality, considered intermediate endpoints, which makes the accelerated approval pathway appropriate, with a commitment for a future confirmatory trial using depression as the primary endpoint.

    Ask Fintool Equity Research AI

    Tom Schrader's questions to Acumen Pharmaceuticals Inc (ABOS) leadership

    Tom Schrader's questions to Acumen Pharmaceuticals Inc (ABOS) leadership • Q2 2025

    Question

    An analyst on behalf of Tom Schrader asked about the range of MMSE scores being tracked in the ALPITUDE trial and the frequency of cognitive testing.

    Answer

    Chief Medical Officer Dr. Eric Siemers clarified that while MMSE is a secondary outcome, the primary outcome is the iADRS scale. He stated that main cognitive assessments are conducted every three months. He also noted that the late 2026 top-line data release will include primary efficacy and safety, with more detailed biomarker results potentially rolling out in the subsequent weeks as assays are completed.

    Ask Fintool Equity Research AI